News and Events
Stay up to date with news and events
Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
Vico Therapeutics recently presented at several conferences to share an interim update on their Phase 1/2a clinical trial testing their drug called VO659, which targets…
Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals
On December 3, 2024 we received word that the very first person received a new drug, called ALN-HTT02, as part of a Phase 1 trial…
Sage Trial Outcome
Sage Trial Outcome – Open Letter to the Community
Self-determination on the HD journey: the role of Advanced Care Planning
Here, we cover a report on Advanced Care Planning (ACP) prepared by clinical researchers at the University College London, reminding us there are things that…
Giving Thanks to the Huntington’s Disease Family Community for Advancing Research
In the spirit of gratitude, this Giving Tuesday, the HDBuzz editorial team would like to reflect on the unique and transformative role the Huntington’s disease…